PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Non-requirement of Reporter Element to Drive Label-free Technology Market - Label-free detection and biomolecular interaction analysis technology, as the name suggests, requires no labels or reporter elements
Non-requirement of Reporter Element to Drive Label-free Technology Market


NewswireToday - /newswire/ - Mountain View, CA, United States, 2008/12/01 - Label-free detection and biomolecular interaction analysis technology, as the name suggests, requires no labels or reporter elements.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


This direct detection has many advantages over traditional detection technologies, the chief among them the screening of protein-protein interactions, which are otherwise a major challenge.

New analysis from Frost & Sullivan (, Advances in Label-free Detection Technologies, finds that large pharmaceutical and biotech companies are showing increasing interest in the technology.

If you are interested in an analysis, which provides manufacturers, end users, and other industry participants with an overview, summary, challenges, and latest coverage of advances in optical networks, then send an email to Mireya Castilla, Corporate Communications, at mireya.castilla[.], with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

Many problems are overcome just by the absence of labels, as they tend to alter the molecules under study, which in turn affects the binding or physicochemical properties. With label-free detection, there is lower interference from compound autofluorescence and color quenching, leading to fewer false positives and negatives. It also does away with the problems cropping up from the secondary detection of auxiliary reagents.

Label-free assays enable the use of natural ligands and substrates, something the label-based assays are unable to support. Besides, label-free technologies help avoid the use of radioactive labels, thereby enhancing lab safety and contributing to cost savings, as there are no radioactive waste disposal costs.

Currently, lack of robust, quality assays for target screening and validation leads to a high 25 percent of targets being ignored. However, label-free technology offers an option to screen the high proportion of orphaned targets, mostly protein-protein interactions. This can be used as a selling point, especially to those pharmaceutical and biotech companies that investigate orphaned targets.

For all its inherent advantages, the high costs of label-free technology can be a restraint to its adoption. Not only are the instruments costly, being priced above $200,000, the cost of the consumables is also high. The fact that the technology is fairly new could also act as a deterrent.

"Probably one of the biggest restraining factors inhibiting the widespread adoption of label-free detection and screening is the overbearing cost of the equipment, which requires capital investment," notes Frost & Sullivan Technical Insights Research Analyst Rasika Ramachandran. "This is compounded by the fact that it is still a budding technology for which the drug discovery customers might not be willing to pay the big buck."

The consumables include Society for Biomolecular Sciences (SBS)-standard microtiter plates embedded with sensors in every well. The sensors are expensive and make this technology costly, especially for academics and specialty pharmaceutical companies that depend on private and venture funding. Larger pharmaceutical and biotech companies with good funding might, however, be able to afford this technology.

"As this is a nascent technology, label-free technology providers can form partnerships with small biotech firms, whereby the technology can be provided at a discounted rate," notes Ramachandran. "The biotech will benefit from the use of a robust new technology, while the label-free company, in addition to the revenues that such a partnership will bring, can use the results obtained through field studies to fine-tune its technology."

Advances in Label-free Detection Technologies, a part of the Technical Insights subscription, provides a technology overview and outlook for the analysis of the label-free technology industry for biomolecular interaction analysis, from a technological and application perspective. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Advances in Label-free Detection Technologies - D12D-55

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Non-requirement of Reporter Element to Drive Label-free Technology Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Mireya Castilla 
210.247.3830 mireya.castilla[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (